Biotech pharma firm ANANDA Scientific Inc. announced last week that the Food and Drug Administration had approved its Investigational New Drug (IND) application for CBD-based Nantheia ATL5 as a potential treatment for opioid use disorder.
The study will be conducted at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
ANANDA’s CEO Sohail R. Zaidi said it is the fourth (IND) approval for the product line and “further reinforces” the company’s vision “of developing CBD as a therapeutic for a number of key indications.”
“This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need.” — Zaidi in a statement
The trial is being funded by the National Institute on Drug Abuse, the firm said in a press release.
According to a summary of the proposal, this research aims to determine the effects and safety of CBD as adjunctive therapy for patients, who have opioid use disorder and are taking buprenorphine + naloxone. The researchers plan to recruit 60 participants from the Tarzana Treatment Center in Los Angeles, California who are currently receiving buprenorphine + naloxone therapy.
The study is planned for about nine weeks.
Edythe London, Ph.D., a distinguished professor of Psychiatry and Biobehavioral Sciences, called the research an “important clinical trial” and a “key milestone for … ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic.”
Get daily cannabis business news updates. Subscribe
Thanks for reading our latest news article. Stay up to date on the latest hemp news, sourced and approved by HempRevs. If you have any questions or comments, please feel free to leave us a message in the comments!
Sign up for our weekly newsletter to stay up to date on the latest Industry news and follow our site for our next post!
Source Disclaimer: This article was was sourced from Ganjapreneur.com (the Original Publisher). In order to maintain the functionality, trust, and safety of HempRevs.com, the content sourced from the Original Publisher may have been altered. Read the original article here:
Biotech Firm Approved by FDA to Study CBD-Based Drug for Opioid Use Disorder